ISIS Pharmaceuticals (ISIS) Reports A Loss For Q1 | Beats Expectations

5

ISIS Pharmaceuticals Stock NewsISIS Pharmaceuticals, Inc. (NASDAQ: ISIS)

As expected, ISIS Pharmaceuticals, Inc. reported their first quarter earnings before the open of the market today. Although the company did report a loss, the loss was more narrow than analysts expected. Today, we’ll talk about what we saw from the earnings report, how the market reacted to the news, and what we can expect to see moving forward.

ISIS Pharmaceuticals Earnings Surpass Wall St. Expectations

As mentioned above, the ISIS Pharmaceuticals earnings report was better than expected. Here’s what we saw…

  • EPS – In the quarter, ISIS generated a loss of $0.14 per share. After adjustments for stock option expense, the losses mounted to $0.03 per share. The average estimate from Wall Street analysts came in at a loss of $0.19 per share.
  • Top Line Revenue – ISIS Pharmaceuticals also beat expectations with regard to top line revenue. In the quarter, the company posted revenue of $62.6 million compared to the $52.3 million expected by analysts.

Subscribe to The Prudent Speculator
All in all, the earnings report was positive.

How ISIS Investors Reacted To The News

Unfortunately, ISIS Pharmaceuticals released their earnings report on a day where we are seeing market wide declines. However, I do think that the positivity from the earnings report has helped to lighten the blow. Nonetheless, ISIS is currently (12:57) trading at $57.86 per share after a loss of 3.02% so far today.

What To Expect Moving Forward

In both the short term and long term outlook, I’m expecting to see the same thing…gains.

  • Short Term – In the short run we have to keep in mind that we are seeing market wide declines today. Market wide declines don’t tend to last long. So, we’ll most likely see a decent market wide recovery relatively soon. Banking on stronger than expected earnings, the uptrend will probably be stronger for ISIS Pharmaceuticals than the average across the board.
  • Long Term – Through their earnings report, ISIS Pharmaceuticals showed a level of strength that investors simply didn’t believe they had in them; that’s a great thing for the stock. Not to mention, their recent deal with Bayer is likely to cause quite a bit of long term growth as well. All in all, I think we’re headed toward long term uptrends my friends!

What Do You Think?

Where do you think ISIS Pharmaceuticals is headed and why? Let us know in the comments below!

5 COMMENTS

  1. Makes no sense why ISIS stock is down today after yesterday’s big agreement with Bayer and the CEO on Mad Money last night talking about the agreement and the other drugs in its pipeline. For its take earnings now really doesn’t matter. Just the guideance and that was practically given to investors yesterday. Earnings were OK despite the loss. Earnings were reasonable. That will now change for future quarters. Market is bad now and ISIS stock is being dropped by it. I have 1000 shares at 66. This should be at least 70 probably 75 by now. There is no good reason for this drop to 57-58 range. It will rip back up soon.

      • @JOSHUA RODRIGUEZ: Thanks. I beleive that investors are not acting rationally when it comes to better biotech. Stocks like JUNO/KITE that have no reveune yet were way too high. ISIS on the other hand has a great pipeline, agreements with big pharma. OK they have losses too but its only to invest in the future business. PS. I am not saying JUNO/KITE etc are bad companies they just have no income now. Its just purely a financial basis decision at this time. I hope that they do become successful businesses in the future and I am sure they will.

  2. Isis is without a doubt a great company and will see a significant uptrend this year. Especially in the second half of the year starting with the news that we know from past data analysis are good.

    I like your site which has good Insights.
    One feedback if I may would be to lessen the ads windows on your site, maybe keep them on the right side only. Keep the interface of your site clean and simple. The readers enjoy that.

LEAVE A REPLY

Please enter your comment!
Please enter your name here